We use cookies for a better user experience. Read our Privacy Policy

I Agree

IBD (Ulcerative Colitis and Crohn's Disease) Treatment Market

IBD [Ulcerative Colitis & Crohn’s Disease] Treatment Market (Drug Class: TNF Inhibitors, Aminosalicylates, Integrin Antagonists, Corticosteroids, and Others) - Global Industry Analysis, Size, Share, Growth, Trends, and Forecast, 2022-2031

IBD (Ulcerative Colitis & Crohn’s Disease) Treatment Market Outlook 2031

  • The global IBD (ulcerative colitis & Cohn's disease) treatment market was valued at US$ 17.3 Bn in 2021
  • The global market is projected to grow at a CAGR of 6.8% from 2022 to 2031
  • The global IBD (ulcerative colitis & Cohn's disease) treatment market is anticipated to reach more than US$ 34.22 Bn by 2031

Analysts’ Viewpoint on IBD (Ulcerative Colitis & Crohn’s Disease) Treatment Market Scenario

Rise in inflammatory bowel disease (IBD) patient pool, approval of new biologic drugs for IBD, novel drugs pipeline, and increase in demand for application of IBD treatment in developing countries are anticipated to propel the global IBD (ulcerative colitis and Crohn’s disease) treatment market. However, high costs could hamper the sales of therapeutics. Reimbursement plans introduced by the leading players to cushion healthcare expenditure will lead to positive sentiment among patients toward effective treatment. Growth in investments in TNF inhibitors is expected to help achieve high ROI, as physicians tend to prescribe these drugs for the treatment of moderate to severe ulcerative colitis. Furthermore, development of anti-adhesion molecules is likely to boost the adoption of integrin antagonists.

Ibd Treatment Market

IBD (Ulcerative Colitis & Crohn’s Disease) Treatment Market Introduction

Rise in prevalence of inflammatory bowel disease (IBD) across the globe is driving the global IBD (Ulcerative Colitis & Crohn’s Disease) treatment market. IBD is a group of gastrointestinal inflammatory diseases that primarily comprises ulcerative colitis and Crohn’s disease. Inflammatory bowel diseases cause long-term chronic inflammation of the gastrointestinal (GI) tract without any known cause. Ulcerative colitis disease mostly affects the inner lining of large intestines and causes inflammation and sores in the colon and rectum. Ulcerative colitis is a more commonly observed disease than Crohn’s disease. It can affect any part of the gastrointestinal tract, starting from the mouth to the small intestine and anus. Common symptoms of IBD include chronic pain and cramps in the abdomen, persistent diarrhea, occasional rectal bleeding, and fever. The exact cause of inflammatory bowel disease is not well understood, and high prevalence and incidence rates of these diseases have been observed in developed countries.

Innovations in product development, approval of drugs, and rising inclination toward the use of biologic and biosimilar drugs are the factors driving the global IBD treatment market. Growth in sales of IBD drugs through online, retail, and hospital pharmacies is helping companies generate more revenues. For instance, in December 2019, the FDA approved two biosimilars – adalimumab and infliximab – for the treatment of Ulcerative Colitis. Biopharmaceutical companies have made significant investments in R&D activities. Large numbers of pipeline products are in different stages of clinical approvals, which are likely to commercialize during the forecast period. Furthermore, high prevalence and incidence of IBD in countries in the West is anticipated to augment the global market. According to a report, around 2.5 million people in the U.S. suffered from inflammatory bowel disease in 2020. The prevalence of IBD among the U.S. population is expected to rise to around 3.5 million by 2030. Similarly, data suggests that the incidence and prevalence of inflammatory bowel diseases [IBD] is still increasing in Europe; around 0.2% of the population of Europe suffered from IBD in 2020.

Request a sample to get extensive insights into the IBD (Ulcerative Colitis & Crohn’s Disease) Treatment Market

COVID-19 Impact on IBD (Ulcerative Colitis & Crohn’s Disease) Treatment Market

The outbreak of COVID-19 has had a negative effect on the global IBD treatment market, as many governments of affected countries gave instructions for the postponement of non-essential surgeries and patient visits. Lockdowns in several countries, travel restrictions, and closure of the diagnostic centers led to a substantial decline in overall diagnostic procedures and treatments. According to two research letters published in JAMA Internal Medicine, there were 6,411 non-COVID-19 hospitalizations, including pediatric inflammatory bowel diseases, in 2019. This data is based on admissions to four hospitals in New York. However, the total admission in 2020 was 3,657 for the same conditions, while the overall decline of non-patients was around 40%. Players operating in the market witnessed a decline in revenue during the financial year 2020. For instance, Pfizer, Inc. registered a decline of -3.5% in revenue generated from its inflammation & immunology segment in 2020. Nevertheless, the market has seen a recovery from COVID-19 impact due to the easing of restrictions by various governments across the globe. Demand for drugs increased in 2021 due to the rise in diagnosis rate of diseases. Leading companies in the market reported an increase in revenue during 2021. Hence, the future IBD treatment market is anticipated to witness recovery at pre-pandemic levels.

Superior Efficacy, Safety, and Better Therapeutic Outcomes Augmenting Adoption of TNF Inhibitors

The TNF inhibitors segment is projected to lead the global IBD (ulcerative colitis and Crohn’s disease) treatment market during the forecast period. The segment's large market share can be ascribed to superior efficacy and safety of drugs in this class in the treatment of IBD, increase in adoption of biologics and biosimilars in countries in the West such as the U.K., France, Germany, and the U.S., and high cost of these drugs. Furthermore, rise in adoption of biologic drugs for the treatment of IBD and high clinical R&D budgets contributed to the TNF inhibitors segment's large share in 2021. TNF inhibitors are used as the second line of treatment when other medications do not work effectively to relieve symptoms of IBD. High adoption of TNF inhibitors owing to promising therapeutic results for the management of IBD, high per capita health care expenditure, and increase in number of hospitalizations can be ascribed to the TNF inhibitors segment's significant market share in 2021.

Request a custom report on IBD (Ulcerative Colitis & Crohn’s Disease) Treatment Market

High Prevalence and Incidence of Ulcerative Colitis to Drive Demand for IBD Treatment

The ulcerative colitis segment accounted for the largest share of the global market in 2021. The trend is expected to continue during the forecast period. High prevalence and incidence of ulcerative colitis in Europe and North America, increase in awareness about the disease, and rise in number of hospitalization cases of ulcerative colitis are the key factors driving the ulcerative colitis segment. An article published on NCBI (2020) stated that ulcerative colitis has an incidence of 9 to 20 cases per 100,000 per year. Its prevalence is 156 to 291 cases per 100,000 per year in North America and Europe. Similarly, in Canada, more than 104,000 people are living with ulcerative colitis and nearly 4,500 cases of ulcerative colitis are diagnosed every year. Furthermore, a recent report suggests that 600,000 to 900,000 people in the U.S. have ulcerative colitis.

Availability of Wide Range of Drugs for IBD Propelling Retail Pharmacies Segment

The retail pharmacies segment dominated the global market in terms of market share in 2021 due to the rise in sale of biologic drugs through retail pharmacy chains in the U.S. Biologic drugs accounted for major share of the IBD treatment market in the U.S. in 2021. Easy availability of drugs such as corticosteroids, Aminosalicylates, and biologics at retail pharmacy stores and usage of these drugs, except biologics, as the first line of treatment is propelling the retail pharmacies segment. Moreover, retail pharmacies are considered the first point of contact for self-medication. In 2019, India had more than 800,000 pharmacies; retail pharmacies are still the dominant medical distribution channel. Hence, presence of a large existing base of retail pharmacy stores in countries such as India, China, the U.S., and Canada is likely to augment the retail pharmacies segment during the forecast period.

Regional Outlook of Global IBD (Ulcerative Colitis & Crohn’s Disease) Treatment Market

North America dominated the global IBD (ulcerative colitis and Crohn’s disease) treatment market in 2021. It is projected to gain major market share by the end of 2031. The region’s dominance of the global market can be ascribed to high prevalence and increase in incidence of ulcerative colitis and Crohn’s disease in the U.S. and Canada, well-established healthcare infrastructure, and high risk of lifestyle-related factors. Additionally, strong product pipeline of key players is projected to drive the global IBD (ulcerative colitis and Crohn’s disease) treatment market in the region.

Asia Pacific is projected to be the fastest growing market for IBD (ulcerative colitis and Crohn’s disease) treatment during the forecast period. Japan dominated the IBD treatment market in the region in 2021. The IBD (ulcerative colitis and Crohn’s disease) treatment market in China is anticipated to grow at a high CAGR during the forecast period. The IBD (ulcerative colitis and Crohn’s disease) treatment market in Latin America and Middle East & Africa is likely to expand at a decent CAGR during the forecast period due to the increase in IBD patient pool and rise in focus of manufacturers on the development of novel therapeutics.

Key Developments in Global IBD (Ulcerative Colitis & Crohn’s Disease) Treatment Market

  • In May 2021, Bristol Myers Squibb announced that the Food and Drug Administration (FDA) approved Zeposia (ozanimod) for the treatment of moderate to severe active ulcerative colitis in adults
  • In September 2019, Janssen Biotech, Inc.’s product, STELARA, was approved for the treatment of moderate to severe active ulcerative colitis in the European Union
  • In April 2019, Salix Pharmaceuticals entered into an exclusive license agreement with Mitsubishi Tanabe Pharma to commercialize and develop late stage investigational S1P modulator for the treatment of inflammatory bowel disease
  • In October 2018, Allergan launched a personalized study approach for clinical research programs in inflammatory bowel disease. These programs would evaluate the efficacy and safety of brazikumab and the potential correlation between biomarkers and the patient outcomes with brazikumab.

Each of these players has been profiled in the IBD (ulcerative colitis & Crohn’s disease) treatment market report based on parameters such as company overview, financial overview, business strategies, product portfolio, business segments, and recent developments.

Global IBD (Ulcerative Colitis & Crohn’s Disease) Treatment Market Snapshot

Attribute

Detail

Market Size Value in 2021

US$ 17.3 Bn

Market Forecast Value in 2031

More than US$ 34.22 Bn

Compound Annual Growth Rate (CAGR)

6.8%

Forecast Period

2022–2031

Historical Data Available for

2017–2021

Quantitative Units

US$ Bn for Value

Market Analysis

It includes segment analysis as well as regional level analysis. Moreover, qualitative analysis includes drivers, restraints, opportunities, key trends, and parent industry overview.

Competition Landscape

  • Market share analysis/ranking by company (2021)
  • Company profiles section includes overview, product portfolio, sales footprint, key subsidiaries or distributors, strategy & recent developments, and key financials

Format

Electronic (PDF) + Excel

Market Segmentation

  • Drug Class
    • TNF Inhibitors
    • Aminosalicylates
    • Integrin Antagonists
    • Corticosteroids
    • Others
  • Disease Indication
    • Ulcerative Colitis
    • Crohn’s Disease
  • Distribution Channel
    • Hospital Pharmacies
    • Retail Pharmacies
    • Online Pharmacies

Regions Covered

  • North America
  • Europe
  • Asia Pacific
  • Latin America
  • Middle East & Africa

Countries Covered

  • U.S.
  • Canada
  • Germany
  • U.K.
  • France
  • Italy
  • Spain
  • China
  • India
  • Japan
  • Australia & New Zealand
  • Brazil
  • Mexico
  • GCC Countries
  • South Africa

Companies Profiled

  • Pfizer, Inc.
  • Janssen Biotech, Inc. (Johnson & Johnson)
  • Health Companies, Inc.
  • Allergan plc
  • Takeda Pharmaceutical Company Limited
  • AbbVie, Inc.
  • Novartis AG
  • UCB, Inc.
  • Biogen, Inc.

Customization Scope

Available upon request

Pricing

Available upon request

IBD (Ulcerative Colitis and Crohn's Disease) Treatment Market

Interested in this report?
Get a FREE Brochure now!

Get Free Brochure

*Get Brochure Report (PDF) sent to your email within minutes

Frequently Asked Questions

How big was the global IBD (ulcerative colitis & Crohn’s disease) treatment market in 2021?

The global IBD (ulcerative colitis & Crohn’s disease) treatment market was valued at US$ 17.3 Bn in 2021

How big will be the global IBD (ulcerative colitis & Crohn’s disease) treatment market in 2031?

The global IBD (ulcerative colitis & Crohn’s disease) treatment market is projected to reach more than US$ 34.22 Bn by 2031

What will be the CAGR of the global IBD (ulcerative colitis & Crohn’s disease) treatment market during the forecast period (2022–2031)?

The global IBD (ulcerative colitis & Crohn’s disease) treatment market is anticipated to grow at a CAGR of 6.8% from 2022 to 2031

Which are the prominent trends that affect market growth?

Increase in incidence of ulcerative colitis and Crohn’s disease is driving the global IBD (ulcerative colitis & Crohn’s disease) treatment market

Which region will account for major share of the global market during the forecast period?

North America is expected to account for major share of the global IBD (ulcerative colitis & Crohn’s disease) treatment market during the forecast period

Who are the prominent players in the global IBD (ulcerative colitis & Crohn’s disease) treatment market?

Pfizer, Inc., Janssen Biotech, Inc. (Johnson & Johnson), Health Companies, Inc., Allergan plc., Takeda Pharmaceutical Company Limited, AbbVie, Inc., Novartis AG, and UCB, Inc.

1. Preface

    1.1. Market Definition and Scope

    1.2. Market Segmentation

    1.3. Key Research Objectives

    1.4. Research Highlights

2. Assumptions and Research Methodology

3. Executive Summary: Global IBD (Ulcerative Colitis and Crohn's Disease) Treatment Market

4. Market Overview

    4.1. Overview

    4.2. Market Dynamics

        4.2.1. Drivers

        4.2.2. Restraints

        4.2.3. Opportunities

    4.3. Global IBD (Ulcerative Colitis and Crohn’s Disease) Treatment Market Value (US$ Mn) Forecast, 2017–2031

5. Key Insights

    5.1. Pipeline Analysis

    5.2. Key Industry Events

    5.3. COVID-19 Pandemic Impact on Industry (value chain and short/mid/long term impact)

6. Global IBD (Ulcerative Colitis and Crohn's Disease) Treatment Market Analysis and Forecast, by Drug Class

    6.1. Introduction & Definition

    6.2. Key Findings/Developments

    6.3. Market Value Forecast, by Drug Class, 2017–2031

        6.3.1. TNF Inhibitors

        6.3.2. Aminosalicylates

        6.3.3. Integrin Antagonists

        6.3.4. Corticosteroids

        6.3.5. Others

    6.4. Market Attractiveness Analysis, by Drug Class

7. Global IBD (Ulcerative Colitis and Crohn's Disease) Treatment Market Analysis and Forecast, by Disease Indication

    7.1. Introduction & Definition

    7.2. Key Findings/Developments

    7.3. Market Value Forecast, by Disease Indication, 2017–2031

        7.3.1. Ulcerative Colitis

        7.3.2. Crohn’s Disease

    7.4. Market Attractiveness Analysis, by Disease Indication

8. Global IBD (Ulcerative Colitis and Crohn's Disease) Treatment Market Analysis and Forecast, by Distribution Channel

    8.1. Introduction & Definition

    8.2. Key Findings/Developments

    8.3. Market Value Forecast, by Distribution Channel, 2017-2031

        8.3.1. Hospital Pharmacies

        8.3.2. Retail Pharmacies

        8.3.3. Online Pharmacies

    8.4. Market Attractiveness Analysis, by Distribution Channel

9. Global IBD (Ulcerative Colitis and Crohn's Disease) Treatment Market Analysis and Forecast, by Region

    9.1. Key Findings

    9.2. Market Value Forecast, by Region

        9.2.1. North America

        9.2.2. Europe

        9.2.3. Asia Pacific

        9.2.4. Latin America

        9.2.5. Middle East & Africa

    9.3. Market Attractiveness Analysis, by Region

10. North America IBD (Ulcerative Colitis and Crohn's Disease) Treatment Market Analysis and Forecast

    10.1. Introduction

        10.1.1. Key Findings

    10.2. Market Value Forecast, by Drug Class, 2017–2031

        10.2.1. TNF Inhibitors

        10.2.2. Aminosalicylates

        10.2.3. Integrin Antagonists

        10.2.4. Corticosteroids

        10.2.5. Others

    10.3. Market Value Forecast, by Disease Indication, 2017–2031

        10.3.1. Ulcerative Colitis

        10.3.2. Crohn’s Disease

    10.4. Market Value Forecast, by Distribution Channel, 2017–2031

        10.4.1. Hospital Pharmacies

        10.4.2. Retail Pharmacies

        10.4.3. Online Pharmacies

    10.5. Market Value Forecast, by Country, 2017–2031

        10.5.1. U.S.

        10.5.2. Canada

    10.6. Market Attractiveness Analysis

        10.6.1. By Drug Class

        10.6.2. By Disease Indication

        10.6.3. By Distribution Channel

        10.6.4. By Country

11. Europe IBD (Ulcerative Colitis and Crohn's Disease) Treatment Market Analysis and Forecast

    11.1. Introduction

        11.1.1. Key Findings

    11.2. Market Value Forecast, by Drug Class, 2017–2031

        11.2.1. TNF Inhibitors

        11.2.2. Aminosalicylates

        11.2.3. Integrin Antagonists

        11.2.4. Corticosteroids

        11.2.5. Others

    11.3. Market Value Forecast, by Disease Indication, 2017–2031

        11.3.1. Ulcerative Colitis

        11.3.2. Crohn’s Disease

    11.4. Market Value Forecast, by Distribution Channel, 2017–2031

        11.4.1. Hospital Pharmacies

        11.4.2. Retail Pharmacies

        11.4.3. Online Pharmacies

    11.5. Market Value Forecast, by Country/Sub-region, 2017–2031

        11.5.1. Germany

        11.5.2. U.K.

        11.5.3. France

        11.5.4. Italy

        11.5.5. Spain

        11.5.6. Rest of Europe

    11.6. Market Attractiveness Analysis

        11.6.1. By Drug Class

        11.6.2. By Disease Indication

        11.6.3. By Distribution Channel

        11.6.4. By Country/Sub-region

12. Asia Pacific IBD (Ulcerative Colitis and Crohn's Disease) Treatment Market Analysis and Forecast

    12.1. Introduction

        12.1.1. Key Findings

    12.2. Market Value Forecast, by Drug Class, 2017–2031

        12.2.1. TNF Inhibitors

        12.2.2. Aminosalicylates

        12.2.3. Integrin Antagonists

        12.2.4. Corticosteroids

        12.2.5. Others

    12.3. Market Value Forecast, by Disease Indication, 2017–2031

        12.3.1. Ulcerative Colitis

        12.3.2. Crohn’s Disease

    12.4. Market Value Forecast, by Distribution Channel, 2017–2031

        12.4.1. Hospital Pharmacies

        12.4.2. Retail Pharmacies

        12.4.3. Online Pharmacies

    12.5. Market Value Forecast, by Country/Sub-region, 2017–2031

        12.5.1. China

        12.5.2. India

        12.5.3. Japan

        12.5.4. Australia & New Zealand

        12.5.5. Rest of Asia Pacific

    12.6. Market Attractiveness Analysis

        12.6.1. By Drug Class

        12.6.2. By Disease Indication

        12.6.3. By Distribution Channel

        12.6.4. By Country/Sub-region

13. Latin America IBD (Ulcerative Colitis and Crohn's Disease) Treatment Market Analysis and Forecast

    13.1. Introduction

        13.1.1. Key Findings

    13.2. Market Value Forecast, by Drug Class, 2017–2031

        13.2.1. TNF Inhibitors

        13.2.2. Aminosalicylates

        13.2.3. Integrin Antagonists

        13.2.4. Corticosteroids

        13.2.5. Others

    13.3. Market Value Forecast, by Disease Indication, 2017–2031

        13.3.1. Ulcerative Colitis

        13.3.2. Crohn’s Disease

    13.4. Market Value Forecast, by Distribution Channel, 2017–2031

        13.4.1. Hospital Pharmacies

        13.4.2. Retail Pharmacies

        13.4.3. Online Pharmacies

    13.5. Market Value Forecast, by Country/Sub-region, 2017–2031

        13.5.1. Brazil

        13.5.2. Mexico

        13.5.3. Rest of Latin America

    13.6. Market Attractiveness Analysis

        13.6.1. By Drug Class

        13.6.2. By Disease Indication

        13.6.3. By Distribution Channel

        13.6.4. By Country/Sub-region

14. Middle East & Africa IBD (Ulcerative Colitis and Crohn's Disease) Treatment Market Analysis and Forecast

    14.1. Introduction

        14.1.1. Key Findings

    14.2. Market Value Forecast, by Drug Class, 2017–2031

        14.2.1. TNF Inhibitors

        14.2.2. Aminosalicylates

        14.2.3. Integrin Antagonists

        14.2.4. Corticosteroids

        14.2.5. Others

    14.3. Market Value Forecast, by Disease Indication, 2017–2031

        14.3.1. Ulcerative Colitis

        14.3.2. Crohn’s Disease

    14.4. Market Value Forecast, by Distribution Channel, 2017–2031

        14.4.1. Hospital Pharmacies

        14.4.2. Retail Pharmacies

        14.4.3. Online Pharmacies

    14.5. Market Value Forecast, by Country/Sub-region, 2017–2031

        14.5.1. GCC Countries

        14.5.2. South Africa

        14.5.3. Rest of Middle East & Africa

    14.6. Market Attractiveness Analysis

        14.6.1. By Drug Class

        14.6.2. By Disease Indication

        14.6.3. By Distribution Channel

        14.6.4. By Country/Sub-region

15. Competition Landscape

    15.1. Market Player - Competition Matrix (by tier and size of companies)

    15.2. Market Share Analysis, by Company, 2021

    15.3. Company Profiles

        15.3.1. AbbVie, Inc.

            15.3.1.1. Company Overview (HQ, Business Segments, Employee Strength)

            15.3.1.2. Product Portfolio

            15.3.1.3. Financial Overview

            15.3.1.4. SWOT Analysis

            15.3.1.5. Strategic Overview

        15.3.2. Allergan plc

            15.3.2.1. Company Overview (HQ, Business Segments, Employee Strength)

            15.3.2.2. Product Portfolio

            15.3.2.3. Financial Overview

            15.3.2.4. SWOT Analysis

            15.3.2.5. Strategic Overview

        15.3.3. Bausch Health Companies, Inc.

            15.3.3.1. Company Overview (HQ, Business Segments, Employee Strength)

            15.3.3.2. Product Portfolio

            15.3.3.3. Financial Overview

            15.3.3.4. SWOT Analysis

            15.3.3.5. Strategic Overview

        15.3.4. Biogen, Inc.

            15.3.4.1. Company Overview (HQ, Business Segments, Employee Strength)

            15.3.4.2. Product Portfolio

            15.3.4.3. Financial Overview

            15.3.4.4. SWOT Analysis

            15.3.4.5. Strategic Overview

        15.3.5. Bristol-Myers Squibb Company

            15.3.5.1. Company Overview (HQ, Business Segments, Employee Strength)

            15.3.5.2. Product Portfolio

            15.3.5.3. Financial Overview

            15.3.5.4. SWOT Analysis

            15.3.5.5. Strategic Overview

        15.3.6. Celltrion Healthcare Co., Ltd.

            15.3.6.1. Company Overview (HQ, Business Segments, Employee Strength)

            15.3.6.2. Product Portfolio

            15.3.6.3. Financial Overview

            15.3.6.4. SWOT Analysis

            15.3.6.5. Strategic Overview

        15.3.7. Janssen Biotech, Inc. (Johnson & Johnson

            15.3.7.1. Company Overview (HQ, Business Segments, Employee Strength)

            15.3.7.2. Product Portfolio

            15.3.7.3. Financial Overview

            15.3.7.4. SWOT Analysis

            15.3.7.5. Strategic Overview

        15.3.8. Novartis AG

            15.3.8.1. Company Overview (HQ, Business Segments, Employee Strength)

            15.3.8.2. Product Portfolio

            15.3.8.3. Financial Overview

            15.3.8.4. SWOT Analysis

            15.3.8.5. Strategic Overview

        15.3.9. Pfizer, Inc.

            15.3.9.1. Company Overview (HQ, Business Segments, Employee Strength)

            15.3.9.2. Product Portfolio

            15.3.9.3. Financial Overview

            15.3.9.4. SWOT Analysis

            15.3.9.5. Strategic Overview

        15.3.10. Takeda Pharmaceutical Company Limited

            15.3.10.1. Company Overview (HQ, Business Segments, Employee Strength)

            15.3.10.2. Product Portfolio

            15.3.10.3. Financial Overview

            15.3.10.4. SWOT Analysis

            15.3.10.5. Strategic Overview

        15.3.11. UCB, Inc.

            15.3.11.1. Company Overview (HQ, Business Segments, Employee Strength)

            15.3.11.2. Product Portfolio

            15.3.11.3. Financial Overview

            15.3.11.4. SWOT Analysis

            15.3.11.5. Strategic Overview

        15.3.12. Other Prominent Players

List of Tables

Table 01: Global IBD (Ulcerative Colitis & Crohn's Disease) Treatment Market Value (US$ Mn) Forecast, by Drug Class, 2017–2031

Table 02: Global IBD (Ulcerative Colitis & Crohn's Disease) Treatment Market Value (US$ Mn) Forecast, by Disease Indication, 2017–2031

Table 03: Global IBD (Ulcerative Colitis & Crohn's Disease) Treatment Market Value (US$ Mn) Forecast, by Distribution Channel, 2017–2031

Table 04: Global IBD (Ulcerative Colitis & Crohn's Disease) Treatment Market Value (US$ Mn) Forecast, by Region, 2017–2031

Table 05: North America IBD (Ulcerative Colitis & Crohn's Disease) Treatment Market Value (US$ Mn) Forecast, by Country, 2017–2031

Table 06: North America IBD (Ulcerative Colitis & Crohn's Disease) Treatment Market Value (US$ Mn) Forecast, by Drug Class, 2017–2031

Table 07: North America IBD (Ulcerative Colitis & Crohn's Disease) Treatment Market Value (US$ Mn) Forecast, by Disease Indication, 2017–2031

Table 08: North America IBD (Ulcerative Colitis & Crohn's Disease) Treatment Market Value (US$ Mn) Forecast, by Distribution Channel, 2017–2031

Table 09: Europe IBD (Ulcerative Colitis & Crohn's Disease) Treatment Market Value (US$ Mn) Forecast, by Country/Sub-region, 2017–2031

Table 10: Europe IBD (Ulcerative Colitis & Crohn's Disease) Treatment Market Value (US$ Mn) Forecast, by Drug Class, 2017–2031

Table 11: Europe IBD (Ulcerative Colitis & Crohn's Disease) Treatment Market Value (US$ Mn) Forecast, by Disease Indication, 2017–2031

Table 12: Europe IBD (Ulcerative Colitis & Crohn's Disease) Treatment Market Value (US$ Mn) Forecast, by Distribution Channel, 2017–2031

Table 13: Asia Pacific IBD (Ulcerative Colitis & Crohn's Disease) Treatment Market Value (US$ Mn) Forecast, by Country/Sub-region, 2017–2031

Table 14: Asia Pacific IBD (Ulcerative Colitis & Crohn's Disease) Treatment Market Value (US$ Mn) Forecast, by Drug Class, 2017–2031

Table 15: Asia Pacific IBD (Ulcerative Colitis & Crohn's Disease) Treatment Market Value (US$ Mn) Forecast, by Disease Indication, 2017–2031

Table 16: Asia Pacific IBD (Ulcerative Colitis & Crohn's Disease) Treatment Market Value (US$ Mn) Forecast, by Distribution Channel, 2017–2031

Table 17: Latin America IBD (Ulcerative Colitis & Crohn's Disease) Treatment Market Value (US$ Mn) Forecast, by Country/Sub-region, 2017–2031

Table 18: Latin America IBD (Ulcerative Colitis & Crohn's Disease) Treatment Market Value (US$ Mn) Forecast, by Drug Class, 2017–2031

Table 19: Latin America IBD (Ulcerative Colitis & Crohn's Disease) Treatment Market Value (US$ Mn) Forecast, by Disease Indication, 2017–2031

Table 20: Latin America IBD (Ulcerative Colitis & Crohn's Disease) Treatment Market Value (US$ Mn) Forecast, by Distribution Channel, 2017–2031

Table 21: Middle East & Africa IBD (Ulcerative Colitis & Crohn's Disease) Treatment Market Value (US$ Mn) Forecast, by Country/Sub-region, 2017–2031

Table 22: Middle East & Africa IBD (Ulcerative Colitis & Crohn's Disease) Treatment Market Value (US$ Mn) Forecast, by Drug Class, 2017–2031

Table 23: Middle East & Africa IBD (Ulcerative Colitis & Crohn's Disease) Treatment Market Value (US$ Mn) Forecast, by Disease Indication, 2017–2031

Table 24: Middle East & Africa IBD (Ulcerative Colitis & Crohn's Disease) Treatment Market Value (US$ Mn) Forecast, by Distribution Channel, 2017–2031

List of Figures

Figure 01: Global IBD (Ulcerative Colitis & Crohn's Disease) Treatment Market Value (US$ Mn) Forecast, 2017–2031

Figure 02: Market Value Share, by Drug Class, 2021

Figure 03: Market Value Share, by Disease Indication, 2021

Figure 04: Market Value Share, by Distribution Channel, 2021

Figure 05: Market Value Share, by Region, 2021

Figure 06: Global IBD (Ulcerative Colitis & Crohn's Disease) Treatment Market Value Share, by Drug Class, 2021 and 2031

Figure 07: Global IBD (Ulcerative Colitis & Crohn's Disease) Treatment Market Attractiveness, by Drug Class, 2022–2031

Figure 08: Global IBD (Ulcerative Colitis & Crohn's Disease) Treatment Market Revenue (US$ Mn) Forecast and Y-o-Y Growth (%) Projection, by TNF Inhibitors, 2017–2031

Figure 09: Global IBD (Ulcerative Colitis & Crohn's Disease) Treatment Market Revenue (US$ Mn) Forecast and Y-o-Y Growth (%) Projection, by Aminosalicylates, 2017–2031

Figure 10: Global IBD (Ulcerative Colitis & Crohn's Disease) Treatment Market Revenue (US$ Mn) Forecast and Y-o-Y Growth (%) Projection, by Integrin Antagonists, 2017–2031

Figure 11: Global IBD (Ulcerative Colitis & Crohn's Disease) Treatment Market Revenue (US$ Mn) Forecast and Y-o-Y Growth (%) Projection, by Corticosteroids, 2017–2031

Figure 12: Global IBD (Ulcerative Colitis & Crohn's Disease) Treatment Market Revenue (US$ Mn) Forecast and Y-o-Y Growth (%) Projection, by Others, 2017–2031

Figure 13: Global IBD (Ulcerative Colitis & Crohn's Disease) Treatment Market Value Share, by Disease Indication, 2021 and 2031

Figure 14: Global IBD (Ulcerative Colitis & Crohn's Disease) Treatment Market Attractiveness, by Disease Indication, 2022–2031

Figure 15: Global IBD (Ulcerative Colitis & Crohn's Disease) Treatment Market Revenue (US$ Mn) Forecast and Y-o-Y Growth (%) Projection, by Ulcerative Colitis, 2017–2031

Figure 16: Global IBD (Ulcerative Colitis & Crohn's Disease) Treatment Market Revenue (US$ Mn) Forecast and Y-o-Y Growth (%) Projection, by Crohn’s Disease, 2017–2031

Figure 17: Global IBD (Ulcerative Colitis & Crohn's Disease) Treatment Market Value Share, by Distribution Channel, 2021 and 2031

Figure 18: Global IBD (Ulcerative Colitis & Crohn's Disease) Treatment Market Attractiveness, by Distribution Channel, 2022–2031

Figure 19: Global IBD (Ulcerative Colitis & Crohn's Disease) Treatment Market Revenue (US$ Mn) Forecast and Y-o-Y Growth (%) Projection, by Hospital Pharmacies, 2017–2031

Figure 20: Global IBD (Ulcerative Colitis & Crohn's Disease) Treatment Market Revenue (US$ Mn) Forecast and Y-o-Y Growth (%) Projection, by Retail Pharmacies, 2017–2031

Figure 21: Global IBD (Ulcerative Colitis & Crohn's Disease) Treatment Market Revenue (US$ Mn) Forecast and Y-o-Y Growth (%) Projection, by Online Pharmacies, 2017–2027

Figure 22: Global IBD (Ulcerative Colitis & Crohn's Disease) Treatment Market Value Share, by Region, 2021 and 2031

Figure 23: Global IBD (Ulcerative Colitis & Crohn's Disease) Treatment Market Attractiveness, by Region, 2022–2031

Figure 24: North America IBD (Ulcerative Colitis & Crohn's Disease) Treatment Market Value (US$ Mn) and Y-o-Y Growth (%) Forecast, 2022–2031

Figure 25: North America IBD (Ulcerative Colitis & Crohn's Disease) Treatment Market Value Share Analysis, by Country, 2021 and 2031

Figure 26: North America IBD (Ulcerative Colitis & Crohn's Disease) Treatment Market Attractiveness Analysis, by Country, 2022–2031

Figure 27: North America IBD (Ulcerative Colitis & Crohn's Disease) Treatment Market Value Share Analysis, by Drug Class, 2021 and 2031

Figure 28: North America IBD (Ulcerative Colitis & Crohn's Disease) Treatment Market Value Share Analysis, by Disease Indication, 2021 and 2031

Figure 29: North America IBD (Ulcerative Colitis & Crohn's Disease) Treatment Market Value Share Analysis, by Distribution Channel, 2021 and 2031

Figure 30: North America IBD (Ulcerative Colitis & Crohn's Disease) Treatment Market Attractiveness Analysis, by Drug Class, 2022–2031

Figure 31: North America IBD (Ulcerative Colitis & Crohn's Disease) Treatment Market Attractiveness Analysis, by Disease Indication, 2022–2031

Figure 32: North America IBD (Ulcerative Colitis & Crohn's Disease) Treatment Market Attractiveness Analysis, by Distribution Channel, 2022–2031

Figure 33: Europe IBD (Ulcerative Colitis & Crohn's Disease) Treatment Market Value (US$ Mn) and Y-o-Y Growth (%) Forecast, 2022–2031

Figure 34: Europe IBD (Ulcerative Colitis & Crohn's Disease) Treatment Market Value Share Analysis, by Country/Sub-region, 2021 and 2031

Figure 35: Europe IBD (Ulcerative Colitis & Crohn's Disease) Treatment Market Attractiveness Analysis, by Country/Sub-region, 2022–2031

Figure 36: Europe IBD (Ulcerative Colitis & Crohn's Disease) Treatment Market Value Share Analysis, by Drug Class, 2021 and 2031

Figure 37: Europe IBD (Ulcerative Colitis & Crohn's Disease) Treatment Market Value Share Analysis, by Disease Indication, 2021 and 2031

Figure 38: Europe IBD (Ulcerative Colitis & Crohn's Disease) Treatment Market Value Share Analysis, by Distribution Channel, 2021 and 2031

Figure 39: Europe IBD (Ulcerative Colitis & Crohn's Disease) Treatment Market Attractiveness Analysis, by Drug Class, 2022–2031

Figure 40: Europe IBD (Ulcerative Colitis & Crohn's Disease) Treatment Market Attractiveness Analysis, by Disease Indication, 2022–2031

Figure 41: Europe IBD (Ulcerative Colitis & Crohn's Disease) Treatment Market Attractiveness Analysis, by Distribution Channel, 2022–2031

Figure 42: Asia Pacific IBD (Ulcerative Colitis & Crohn's Disease) Treatment Market Value (US$ Mn) Forecast and Y-o-Y Growth (%) Projection, 2017–2031

Figure 43: Asia Pacific IBD (Ulcerative Colitis & Crohn's Disease) Treatment Market Value Share, by Country/Sub-region, 2021 and 2031

Figure 44: Asia Pacific IBD (Ulcerative Colitis & Crohn's Disease) Treatment Market Attractiveness, by Country/Sub-region, 2022–2031

Figure 45: Asia Pacific IBD (Ulcerative Colitis & Crohn's Disease) Treatment Market Value Share, by Drug Class, 2021 and 2031

Figure 46: Asia Pacific IBD (Ulcerative Colitis & Crohn's Disease) Treatment Market Value Share, by Disease Indication, 2021 and 2031

Figure 47: Asia Pacific IBD (Ulcerative Colitis & Crohn's Disease) Treatment Market Value Share, by Distribution Channel, 2021 and 2031

Figure 48: Asia Pacific IBD (Ulcerative Colitis & Crohn's Disease) Treatment Market Attractiveness, by Drug Class, 2022–2031

Figure 49: Asia Pacific IBD (Ulcerative Colitis & Crohn's Disease) Treatment Market Attractiveness, by Disease Indication, 2022–2031

Figure 50: Asia Pacific IBD (Ulcerative Colitis & Crohn's Disease) Treatment Market Attractiveness, by Distribution Channel, 2022–2031

Figure 51: Latin America IBD (Ulcerative Colitis & Crohn's Disease) Treatment Market Value (US$ Mn) and Y-o-Y Growth (%) Forecast, 2022–2031

Figure 52: Latin America IBD (Ulcerative Colitis & Crohn's Disease) Treatment Market Value Share Analysis, by Country/Sub-region, 2021 and 2031

Figure 53: Latin America IBD (Ulcerative Colitis & Crohn's Disease) Treatment Market Attractiveness Analysis, by Country/Sub-region, 2017–2025

Figure 54: Latin America IBD (Ulcerative Colitis & Crohn's Disease) Treatment Market Value Share Analysis, by Drug Class, 2021 and 2031

Figure 55: Latin America IBD (Ulcerative Colitis & Crohn's Disease) Treatment Market Value Share Analysis, by Disease Indication, 2021 and 2031

Figure 56: Latin America IBD (Ulcerative Colitis & Crohn's Disease) Treatment Market Value Share Analysis, by Distribution Channel, 2021 and 2031

Figure 57: Latin America IBD (Ulcerative Colitis & Crohn's Disease) Treatment Market Attractiveness Analysis, by Drug Class, 2022–2031

Figure 58: Latin America IBD (Ulcerative Colitis & Crohn's Disease) Treatment Market Attractiveness Analysis, by Disease Indication, 2022–2031

Figure 59: Latin America IBD (Ulcerative Colitis & Crohn's Disease) Treatment Market Attractiveness Analysis, by Distribution Channel, 2022–2031

Figure 60: Middle East & Africa IBD (Ulcerative Colitis & Crohn's Disease) Treatment Market Value (US$ Mn) Forecast and Y-o-Y Growth (%) Projection, 2017–2031

Figure 61: Middle East & Africa IBD (Ulcerative Colitis & Crohn's Disease) Treatment Market Value Share, by Country/Sub-region, 2021 and 2031

Figure 62: Middle East & Africa IBD (Ulcerative Colitis & Crohn's Disease) Treatment Market Attractiveness, by Country/Sub-region, 2022–2031

Figure 63: Middle East & Africa IBD (Ulcerative Colitis & Crohn's Disease) Treatment Market Value Share, by Drug Class, 2021 and 2031

Figure 64: Middle East & Africa IBD (Ulcerative Colitis & Crohn's Disease) Treatment Market Value Share, by Disease Indication, 2021 and 2031

Figure 65: Middle East & Africa IBD (Ulcerative Colitis & Crohn's Disease) Treatment Market Value Share, by Distribution Channel, 2021 and 2031

Figure 66: Middle East & Africa IBD (Ulcerative Colitis & Crohn's Disease) Treatment Market Attractiveness, by Drug Class, 2022–2031

Figure 67: Middle East & Africa IBD (Ulcerative Colitis & Crohn's Disease) Treatment Market Attractiveness, by Disease Indication, 2022–2031

Figure 68: Middle East & Africa IBD (Ulcerative Colitis & Crohn's Disease) Treatment Market Attractiveness, by Distribution Channel, 2022–2031

Transparency Market Research Plus
  • We offer 100% free customisation with our Enterprise License!!
  • Get a free copy if the report you purchased is updated within 90 days
  • Regardless from where you have purchased the report, you can request an updated version of the report from us.

Complete the form below and we'll get back to you shortly.

480

Your personal details are safe with us. Privacy Policy*

Copyright © Transparency Market Research, Inc. All Rights reserved